Japan· JP-2329021D1071
レバミピド
A rebamipid product containing レバミピド, registered in Japan by 高田製薬, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- レバミピド
- Manufacturer
- 高田製薬
- Country
- Japan (JP)
- ATC code
- A02BX14
- ATC class
- Rebamipid
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under A02BX14
Rebamipid, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/604c91cf-2aa1-48f6-8e46-1b61314ac7d6 GET /v1/drugs/604c91cf-2aa1-48f6-8e46-1b61314ac7d6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "２０％１ｇ",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "2329021D1071",
"category": "内用薬",
"price_yen": 14.5,
"generic_name": "レバミピド",
"product_name_jp": null,
"therapeutic_class": "2329",
"transitional_expiry": null
}See everything about rebamipid.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.